线粒体
细胞凋亡
程序性细胞死亡
胞浆
过氧化氢酶
活性氧
线粒体ROS
细胞生物学
细胞色素c
生物
分子生物学
细胞培养
细胞
化学
氧化应激
生物化学
酶
遗传学
作者
Yuko Arita,S. Hella Harkness,Jeffrey A. Kazzaz,Hshi-chi Koo,Ansamma Joseph,J. Andrés Melendez,Jonathan M. Davis,A. Chander,Yuchi Li
出处
期刊:American Journal of Physiology-lung Cellular and Molecular Physiology
[American Physical Society]
日期:2005-12-31
卷期号:290 (5): L978-L986
被引量:46
标识
DOI:10.1152/ajplung.00296.2005
摘要
Reactive oxygen species (ROS) can cause cell injury and death via mitochondrial-dependent pathways, and supplementation with antioxidants has been shown to ameliorate these processes. The c-Jun NH 2 -terminal kinase (JNK) pathway has been shown to play a critical role in ROS-induced cell death. To determine if targeting catalase (CAT) to the mitochondria provides better protection than cytosolic expression against H 2 O 2 -induced injury, the following two approaches were taken: 1) adenoviral-mediated transduction was performed using cytosolic (CCAT) or mitochondrial (MCAT) CAT cDNAs and 2) stable cell lines were generated overexpressing CAT in mitochondria ( n = 3). Cells were exposed to 250 μM H 2 O 2 , and cell survival, mitochondrial function, cytochrome c release, and JNK activity were analyzed. Although all viral transduced cells had a transient twofold increase in CAT activity, MCAT cells had significantly higher survival rates, the best mitochondrial function, and lowest JNK activity compared with CCAT and LacZ controls. The improved protection with MCAT was observed in primary type II lung epithelial cells and in transformed lung epithelial cells. In the three stable cell lines, cell survival directly correlated with extent of mitochondrial localization ( r = 0.60572, P < 0.05) and not overall CAT activity ( r = −0.45501, P < 0.05). Data indicate that targeting of antioxidants directly to the mitochondria is more effective in protecting lung epithelial cells against ROS-induced injury. This has important implications in antioxidant supplementation trials to prevent ROS-induced lung injury in critically ill patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI